Ultimo aggiornamento :
14/12/2024
farmaco contro il cancro   Vinorelbine tartrate  
Iniezione
Stabilità in soluzione Stabilità in miscela Fattori che influenzano la stabilità Compatibilità metodo di iniezione Bibliografia pdf
   Struttura chimica  

Nome commerciale   Nome commerciale     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eberelbin Iran
Eunexon Perù
Eurovinorelbin Germania
Navelbin Ungheria
Navelbine Arabia Saudita, Argentina, Australia, Austria, Belgio, Chile, Colombia, Danimarca, Egitto, Emirati Arabi Uniti, Finlandia, Francia, Germania, Gran Bretagna, Grecia, India, Iran, Irlanda, Islanda, Italia, Lussemburgo, Malaysia, Messico, Norvegia, nuova Zelanda, Perù, Polonia, Portogallo, Romania, Spagna, Stati Uniti d’America, Svezia, Svizzera, Tunisia, Turchia
Navildez Messico
Navin Germania
Navirel Germania, Norvegia, Svezia
Okabine Perù
Relbinalur Svezia
Renovel Turchia
Setroxin Messico
Sulcoline Argentina
Tarckorel Messico, Perù
Vieby Messico
Viessia Colombia, Messico, Venezuela
Vilne Argentina, Ecuador, Perù
Vinarine Argentina, Perù, Venezuela
Vinelbine Malaysia
Vinilex Messico
Vinkebir Argentina, Perù
Vinobina Colombia
Vinobur Svezia
Vinolbin Germania
Vinorel Argentina, Perù
Vinorelbin Austria, Belgio, Ecuador, Germania, Islanda, Norvegia, Romania, Svezia, Svizzera
Vinorelbina Colombia, Ecuador, Messico, Perù, Romania, Spagna
Vinorelbine Argentina, Belgio, Canada, Gran Bretagna, Iran, nuova Zelanda, Stati Uniti d’America, Svizzera
Vinorgen Chile, Perù
Zinavin Colombia
Bibliografia   Iniezione   Bibliografia : Vinorelbine tartrate  
tipo pubblicazione
84 Rivista Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
144 Rivista Dine T, Luyckx M, Cazin JC, Goudaliez F, Mallevais ML.
Stability and compatibility studies of vinblastine, vincristine, vindesine and vinorelbine with PVC infusion bags.
Int J Pharm 1991 ; 77: 279-285.
182 Rivista Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Rivista Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
251 Rivista Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 Rivista Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
905 Rivista Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Rivista Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1070 Rivista Balthasar JP.
Concentration-dependent incompatibility of vinorelbine tartrate and heparin sodium.
Am J Health-Syst Pharm 1999 ; 56: 1891.
1413 Rivista Lieu CL, Chin A, Gill MA.
Five-day stability of vinorelbine in 5% dextrose injection and in 0.9% sodium chloride injection at room temperature.
Int J Pharm Compound 1999 ; 3: 67-68.
1423 Rivista Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1501 Rivista Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratorio Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1625 Rivista Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Rivista Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
2260 Laboratorio Stability of vinorelbin "Ebewe" infusion solutions.
Ebewe Pharma 2007
3128 Laboratorio Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3474 Laboratorio Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3595 Laboratorio Aciclovir - Summary of Product Characteristics
Hospira 2009
3641 Laboratorio Vinorelbine (Navelbine®) - Summary of Product Characteristics
Pierre Fabre 2011
3644 Laboratorio Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3838 Laboratorio Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4471 Laboratorio Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019

  Mentions Légales